Bio­phar­ma and medtech mar­kets ad­vance to­ward equi­lib­ri­um: 2024 life sci­ences clus­ter analy­sis

8 months ago

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

8 months ago

CMIC: Japan’s lead­ing CRO fo­cus­es on the fu­ture of clin­i­cal tri­als with in­no­va­tion and dig­i­tal so­lu­tions

8 months ago

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

9 months ago

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

9 months ago

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just that

9 months ago

The role of AI in pre­dic­tive bio­mark­er pa­tient match­ing

10 months ago

A life­time of change: mak­ing decades of dif­fer­ence in IgAN dis­ease man­age­ment

10 months ago

Hy­brid Clin­i­cal Tri­als: Chang­ing the dy­nam­ic and build­ing a more ef­fi­cient tri­al ecosys­tem.

10 months ago

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

11 months ago

END­POINTS WE­BI­NAR: CD­MOs’ crit­i­cal role in a rapid­ly evolv­ing bio­phar­ma land­scape

11 months ago

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

Last year

A nov­el study in­sight an­a­lyt­ics (SIA) method­ol­o­gy im­proves PANSS da­ta qual­i­ty and sig­nal de­tec­tion in a glob­al clin­i­cal tri­al in schiz­o­phre­nia

Last year

Back to the fu­ture: From tar­get-se­lec­tive drug de­sign to AI-en­abled polyphar­ma­col­o­gy

Last year

The M&A pool set to ac­cel­er­ate biotech in­no­va­tion

Last year

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Last year

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

Last year

Be­yond tra­di­tion: re­defin­ing FIH on­col­o­gy small mol­e­cule tri­als with healthy vol­un­teers

Last year

Will the biotech re­bound run in­to pric­ing pol­i­cy ob­sta­cles?

Last year

How spon­sors can stay bull­ish in an ever-chang­ing mar­ket

Last year

McKesson - For­tune top 10 health­care com­pa­ny - looks to the fu­ture of da­ta with Com­pile ac­qui­si­tion

Last year

Near-term strate­gies for biotech drug de­vel­op­ers fac­ing shift­ing health­care dy­nam­ics

Last year

Bou­tique biotech agency guar­an­tees re­cruit­ment to drug spon­sors

Last year

Ful­ly Char­ac­ter­iz­ing a Man­u­fac­tur­ing Process is Crit­i­cal for Ad­vanc­ing Gene Ther­a­pies and Pri­or­i­tiz­ing Pa­tient Safe­ty

Last year
First page Previous page 12345 Next page Last page
A service from the Financial Times